Right, these three interventions each target specific damage categories in the SENS framework, and they're absolutely essential for comprehensive rejuvenation. Combining senotherapeutics with regenerative medicine, immunotherapy, and lifestyle interventions may yield synergistic effects that restore tissue function while removing or suppressing cellular damage. Let me break down their distinct roles. Senolytics selectively kill senescent cells - the zombie cells that accumulate with age and poison surrounding tissue through their inflammatory secretions. Current therapies are focused on elimination of senescent cell functions in three main ways: i) use of senolytics; ii) inhibition of SASP; and iii) improvement of immune system functions against senescent cells (immunosurveillance). An option to eliminate the negative effects of chronic senescent cells is to kill them specifically, using compounds called senolytics. Senolytics target key proteins mainly involved in apoptosis, such as Bcl-2, Bcl-XL, p53, p21, PI3K, AKT, FOXO4 and p53. Dasatinib plus quercetin, navitoclax, and fisetin are among our most promising senolytics. Senolytic pre-treatment may improve the engraftment and efficacy of stem cell therapies by clearing the inflammatory milieu. The beauty is we're not trying to slow senescence - we're removing the damage after it accumulates. Stem cells address the opposite problem - cell loss and tissue atrophy, my first SENS damage category. We lose functional cells in critical tissues as we age - muscle, brain, immune system. Stem cell therapies replace these losses directly. Stem cells are a sub population of cell types that form the foundation of our body, and have the potential to replicate, replenish and repair limitlessly to maintain the tissue and organ homeostasis. But there's a critical interaction here - their long-term persistence fosters a deleterious milieu that disrupts tissue homeostasis, impairs stem cell function, and promotes chronic inflammation and fibrosis. This is why sequencing matters. Clear senescent cells first to create a hospitable environment, then introduce fresh stem cells for tissue regeneration. We're seeing this work brilliantly in our RMR studies. Crosslink breakers target my most neglected damage category - extracellular matrix crosslinks. These molecular handcuffs stiffen arteries, reduce tissue elasticity, and drive hypertension. The lack of crosslink breaker development has been a major gap in the field, which is why I've long advocated for more research here. Glucosepane is the primary culprit in humans, but we've struggled to develop effective breakers. The chemistry is challenging - you need to cleave the crosslink without damaging the surrounding proteins. Still, this category is absolutely essential. You can clear all the senescent cells and replace all the lost cells you want, but if your arteries are stiff as concrete from crosslinks, you'll still have cardiovascular problems. The engineering logic is crystal clear: each intervention addresses distinct damage types that accumulate independently. Senolytics remove poison-spewing cells, stem cells replace lost tissue, crosslink breakers restore elasticity. Combinatorial approaches, such as pairing senolytics with senomorphics, anti-inflammatory agents, or regenerative therapies, may help address the complex interplay between senescent cells and their microenvironment. That's precisely why our RMR2 study combines multiple interventions. No single approach addresses all seven damage categories. We need the full toolkit working in concert - that's how we'll achieve robust rejuvenation and longevity escape velocity. Additional sources: https://www.mdpi.com/2218-273X/15/6/860 https://pmc.ncbi.nlm.nih.gov/articles/PMC12190739/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6949083/